Fly News Breaks for June 25, 2019
Jun 25, 2019 | 15:49 EDT
Janney Montgomery Scott analyst Esther Hong said she believes today's selloff in Aldeyra shares after the company announced its Phase 3 SOLACE trial of reproxalap in Noninfectious Anterior Uveitis, or NAU, did not achieve statistical significance has been overdone, arguing that the company has a "significantly larger" opportunity in Dry Eye Disease, or DED. Hong maintains a Buy rating on Aldeyra shares.
News For ALDX From the Last 2 Days
There are no results for your query ALDX